Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for ...

The side effect is rare, according to a new study, but is also the subject of multiple lawsuits, including two filed by Long ...

Denmark’s economy rebounded in the second quarter, as the strength of the broader pharmaceuticals industry helped to outweigh ...

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

This is an audio transcript of the FT News Briefing podcast episode: ‘What to expect from Jay Powell’s Jackson Hole speech’ Sonja Hutson Good morning from the Financial Times. Today is Wednesday, ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Diabetic medicine Ozempic now approved by Health Canada to reduce the risk of further kidney decline among patients with Type ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Over 1,800 lawsuits claim Ozempic caused stomach paralysis, vision loss, and more. Read what’s next in the legal fight.